Castle Biosciences FY2025 revenue up 4% to $344M, net loss of $24.2M vs income of $18.2M in 2024

CASTLE BIOSCIENCES INC

2025-FY EPS reported -$0.83 revenue$344,229,000

FY2025 revenue $344.2M (+4% YoY); excluding discontinued tests growth 34%. Core test reports (DecisionDx-Melanoma, TissueCypher) +37%.
Q4 revenue $87.0M (+1%); core reports +42%. TissueCypher reports up 86% in FY2025.
Net loss $24.2M ($0.83 loss per share) vs net income $18.2M ($0.66 EPS) in 2024. Adj. net loss per share $0.14.
Adjusted EBITDA $44.0M (FY2025) vs $75.0M (2024); net cash from ops $64.3M; cash & securities $299.5M at year-end.
2026 revenue guidance $340-350M; AdvanceAD-Tx limited launch; multiple publications support test utility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.